TABLE 1.
Clinical development of H2S-releasing compound.
| Name | Description | Indications | Development phase | References |
| Zofenopril | ACE inhibitor combined to an H2S donor | Hypertension | Approved | (136, 137) |
| ATB-340 | H2S-releasing derivative of low dose aspirin | Anti-thrombotic for chronic prevention of cardiovascular diseases and cancer chemoprevention | Dropped | (139) |
| ATB-352 | H2S-releasing derivative of ketoprofen | NSAID | Pre-clinical | (153) |
| ATB-346 Otenaproxesul |
H2S-releasing derivative of naproxen | NSAID; Gastric Ulcer, Osteoarthritis | Phase II NCT03978208 NCT03291418 |
(140) |
| S-Diclofenac | Derivative of Diclofenac combined to an H2S donor | NSAID | Pre-clinical; Dropped? | (141–143) |
| IK-1001 | Injectable stable form of Na2S | Reduction of heart complications during coronary artery bypass graft | Stopped during phase 2 trial NCT00858936 |
(144) |
| SG1002 | H2S-releasing prodrug | Heart failure | Phase 1 NCT02278276 |
(146) |
| Sodium thiosulfate | Inorganic sodium salt with thiosulfate ions | Calciphylaxis (ESRD) and cyanide poisoning | Approved NCT00568399 NCT01008631 NCT03150420 NCT02899364 |
(149, 154) |
NSAID, Non-steroidal anti-inflammatory drug; ESRD, End Stage Renal disease.